PLACEBOS AND PRINCIPLES - A TRIAL OF ONDANSETRON

被引:17
作者
CITRON, ML
机构
关键词
ONDANSETRON; PLACEBO; ETHICS; MEDICAL; NAUSEA; VOMITING;
D O I
10.7326/0003-4819-118-6-199303150-00013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Special ethical concerns exist about the use of placebo controls. A placebo-controlled study must answer four questions: (1) Was any therapeutic intervention available that could be reasonably assumed to be less harmful than the placebo control? (2) Did the placebo control pose more than minimal risk to those patients? (3) Was the study designed in every way possible to minimize potential harm to the patients receiving placebo? (4) Were the patients fully and accurately informed of the additional risk of being in the placebo group? By answering these questions, the author evaluates a study comparing oral ondansetron to placebo for cancer patients receiving emetogenic chemotherapy.
引用
收藏
页码:470 / 471
页数:2
相关论文
共 15 条
  • [1] A DOUBLE-BLIND TRIAL COMPARING ANTIEMETIC EFFICACY AND TOXICITY OF METOCLOPRAMIDE VERSUS METHYLPREDNISOLONE VERSUS DOMPERIDONE IN PATIENTS RECEIVING DOXORUBICIN CHEMOTHERAPY ALONE OR IN COMBINATION WITH OTHER ANTIBLASTIC AGENTS
    BASURTO, C
    ROILA, F
    BRACARDA, S
    TONATO, M
    BALLATORI, E
    DELFAVERO, A
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (05): : 594 - 596
  • [2] EFFICACY OF ORAL ONDANSETRON IN THE PREVENTION OF EMESIS IN OUTPATIENTS RECEIVING CYCLOPHOSPHAMIDE-BASED CHEMOTHERAPY
    BECK, TM
    CIOCIOLA, AA
    JONES, SE
    HARVEY, WH
    TCHEKMEDYIAN, NS
    CHANG, A
    GALVIN, D
    HART, NE
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (06) : 407 - 413
  • [3] BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, P51
  • [4] Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting - A Multicenter, Randomized, Double-Blind, Crossover Study
    Demulder, PHM
    Seynaeve, C
    Vermorken, JB
    Vanliessum, PA
    Molsjevdevic, S
    Allman, EL
    Beranek, P
    Verweij, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 113 (11) : 834 - 840
  • [5] GRALLA RJ, 1989, CANCER PRINCIPLES PR, V2, P2137
  • [6] A SINGLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON, A SELECTIVE SEROTONIN ANTAGONIST, WITH INTRAVENOUS METOCLOPRAMIDE IN THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE CISPLATIN CHEMOTHERAPY
    HAINSWORTH, J
    HARVEY, W
    PENDERGRASS, K
    KASIMIS, B
    OBLON, D
    MONAGHAN, G
    GANDARA, D
    HESKETH, P
    KHOJASTEH, A
    HARKER, G
    YORK, M
    SIDDIQUI, T
    FINN, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) : 721 - 728
  • [7] NAUSEA AND VOMITING AS MAJOR COMPLICATIONS OF CANCER-CHEMOTHERAPY
    LASZLO, J
    [J]. DRUGS, 1983, 25 : 1 - 7
  • [8] ANTIEMETIC EFFICACY OF DEXAMETHASONE RANDOMIZED, DOUBLE-BLIND, CROSSOVER STUDY WITH PROCHLORPERAZINE IN PATIENTS RECEIVING CANCER-CHEMOTHERAPY
    MARKMAN, M
    SHEIDLER, V
    ETTINGER, DS
    QUASKEY, SA
    MELLITS, ED
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (09) : 549 - 552
  • [9] COMPARISON OF THE 5-HYDROXYTRYPTAMINE3 (SEROTONIN) ANTAGONIST ONDANSETRON (GR-38032F) WITH HIGH-DOSE METOCLOPRAMIDE IN THE CONTROL OF CISPLATIN-INDUCED EMESIS
    MARTY, M
    POUILLART, P
    SCHOLL, S
    DROZ, JP
    AZAB, M
    BRION, N
    PUJADELAURAINE, E
    PAULE, B
    PAES, D
    BONS, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (12) : 816 - 821
  • [10] SLEDGE GW, 1992, CANCER, V70, P2524, DOI 10.1002/1097-0142(19921115)70:10<2524::AID-CNCR2820701022>3.0.CO